Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pereira Isabela A G, Mendonça Débora V C, Tavares Grasiele S V, Lage Daniela P, Ramos Fernanda F, Oliveira-da-Silva João A, Antinarelli Luciana M R, Machado Amanda S, Carvalho Lívia M, Carvalho Ana Maria R S, Salustiano Iorrana V, Reis Thiago A R, Bandeira Raquel S, Silva Alessandra M, Martins Vívian T, Chávez-Fumagalli Miguel A, Humbert Maria V, Roatt Bruno M, Duarte Mariana C, Menezes-Souza Daniel, Coimbra Elaine S, Leite João Paulo V, Coelho Eduardo A F, Gonçalves Denise U
Аннотация
METHODS AND RESULTS: In this study, the antileishmanial activity of a diprenylated flavonoid called 5,7,3,4'-tetrahydroxy-6,8-diprenylisoflavone (CMt) was tested against Leishmania infantum and L amazonensis species. Results showed that CMt presented selectivity index (SI) of 70.0 and 165.0 against L infantum and L amazonensis promastigotes, respectively, and of 181.9 and 397.8 against respective axenic amastigotes. Amphotericin B (AmpB) showed lower SI values of 9.1 and 11.1 against L infantum and L amazonensis promastigotes, respectively, and of 12.5 and 14.3 against amastigotes, respectively. CMt was effective in the treatment of infected macrophages and caused alterations in the parasite mitochondria. L infantum-infected mice treated with miltefosine, CMt alone or incorporated in polymeric micelles (CMt/Mic) presented significant reductions in the parasite load in distinct organs, when compared to the control groups. An antileishmanial Th1-type cellular and humoral immune response were developed one and 15 days after treatment, with CMt/Mic-treated mice presenting a better protective response.
CONCLUSION: Our data suggest that CMt/Mic could be evaluated as a chemotherapeutic agent against VL.